Melanoma in immunosuppressed patients

Mayo Clinic Proceedings

Volumn 87, Issue 10, 2012, Pages 991-1003

  Kubica, Agnieszka W ^a   Brewer, Jerry D ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ALKYLATING AGENT; AZATHIOPRINE; BREQUINAR; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; IPILIMUMAB; LEFLUNOMIDE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE DERIVATIVE; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; VEMURAFENIB;

BCL 2 GENE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSAL ATTRIBUTION; CD4+ CD25+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GRAFT RECIPIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; NONHODGKIN LYMPHOMA; NONHUMAN; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PATHOGENESIS; PROTO ONCOGENE; REGULATORY T LYMPHOCYTE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SUN EXPOSURE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT INDICATION; TUMOR IMMUNITY; ULTRAVIOLET RADIATION; CELL TRANSFORMATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; PATHOLOGY; SKIN TUMOR; SUNLIGHT;

CELL TRANSFORMATION, NEOPLASTIC; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSION; LYMPHOPROLIFERATIVE DISORDERS; MELANOMA; ORGAN TRANSPLANTATION; RISK FACTORS; SKIN NEOPLASMS; SUNLIGHT;

EID: 84871858163     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.04.018     Document Type: Review

References (100)

1. Belloni-Fortina A, Piaserico S, Tonin E, Alaibac M. Melanoma and immunosuppression. Dermatology. 2009;218(1):88.
2. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77(7):303-310.
3. Marshall JA, Forster TH, Purdie DM, et al. Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma. Immunol Cell Biol. 2006;84(3):295-302.
4. Menzies SW, McCarthy WH. Complete regression of primary cutaneous malignant melanoma. Arch Surg. 1997;132(5):553-556.
5. Brewer JD, Christenson LJ, Weaver AL, et al. Malignant melanoma in solid transplant recipients: collection of database cases and comparison with Surveillance, Epidemiology, and End Results data for outcome analysis. Arch Dermatol. 2011; 147(7):790-796.
6. Matin RN, Mesher D, Proby CM, et al; Skin Care in Organ Transplant Patients, Europe (SCOPE) group. Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases. Am J Transplant. 2008;8(9):1891-1900.
7. Brewer JD, Shanafelt TD, Otley CC, et al. Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study. J Clin Oncol. 2012;30(8):843-849.
8. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008;13(suppl 4):2-9.
9. McCarter MD, Baumgartner J, Escobar GA, et al. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol. 2007;14(10):2854-2860.
10. Baumgartner J, Wilson C, Palmer B, Richter D, Banerjee A, McCarter M. Melanoma induces immunosuppression by upregulating FOXP3(-) regulatory T cells. J Surg Res. 2007; 141(1):72-77.
11. Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4-CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004;173(2):1444-1453.
12. Polak ME, Borthwick NJ, Gabriel FG, et al. Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer. 2007;96(12):1879-1887.
13. Kirkwood JM, Tarhini AA, Panelli MC, et al. Next generation of immunotherapy for melanoma. J Clin Oncol. 2008;26(20):3445- 3455.
14. Zhang QJ, Seipp RP, Chen SS, et al. TAP expression reduces IL-10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma. Int J Cancer. 2007; 120(9):1935-1941.
15. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800.
16. [published correction appears in Nat Med. 2002;8(9):1039]
17. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114(8):1537-1544.
18. Martinez-Lorenzo MJ, Anel A, Alava MA, et al. The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles: possible contribution to tumor counterattack. Exp Cell Res. 2004;295(2):315-329.
19. Pietra G, Manzini C, Rivara S, et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res. 2012; 72(6):1407-1415.
20. Garibyan L, Fisher DE. How sunlight causes melanoma. Curr Oncol Rep. 2010;12(5):319-326.
21. Otley CC, Pittelkow MR. Skin cancer in liver transplant recipients. Liver Transplant. 2000;6(3):253-262.
22. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681-1691.
23. Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7):1221-1227.
24. Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet. 2000; 355(9218):1886-1887.
25. Lindelöf B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol. 2000;143(3):513-519.
26. Brewer JD. Melanoma in immunosuppressed patients [editorial]. Exp Rev Dermatol. 2010;5(3):247-250.
27. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40(2, pt 1):177-186.
28. Vajdic CM, van Leeuwen MT, Webster AC, et al. Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev. 2009;18(8):2297-2303.
29. Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol. 2006;154(3):498-504.
30. Le Mire L, Hollowood K, Gray D, Bordea C, Wojnarowska F. Melanomas in renal transplant recipients. Br J Dermatol. 2006; 154(3):472-477.
31. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006; 296(23):2823-2831.
32. Hollenbeak CS, Todd MM, Billingsley EM, Harper G, Dyer AM, Lengerich EJ. Increased incidence of melanoma in renal transplantation recipients. Cancer. 2005;104(9):1962-1967.
33. Webster A, Chapman J. Cancer report. In: McDonald S, Excell L, eds. The Twenty Eight Report: Australia and New Zealand Dialysis and Transplant Registry. Australia & New Zealand: ANZDATA Registry; 2005:132-141.
34. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905-913.
35. Leveque L, Dalac S, Dompmartin A, et al. Melanoma in organ transplant patients [in French]. Ann Dermatol Venereol. 2000; 127(2):160-165.
36. Jain AB, Yee LD, Nalesnik MA, et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation. 1998;66(9):1193-1200.
37. Penn I. De novo malignancies in pediatric organ transplant recipients. Pediatr Transplant. 1998;2(1):56-63.
38. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow-up study. Transplantation. 1996;61(5):715-721.
39. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer. 1995;60(2):183-189.
40. Sheil AG, Flavel S, Disney AP, Mathew TH, Hall BM. Cancer incidence in renal transplant patients treated with azathioprine or cyclosporine. Transplant Proc. 1987;19(1, pt 3):2214-2216.
41. Dinh QQ, Chong AH. Melanoma in organ transplant recipients: the old enemy finds a new battleground. Australasian J Dermatol. 2007;48(4):199-207.
42. Zattra E, Fortina AB, Bordignon M, Piaserico S, Alaibac M. Immunosuppression and melanocyte proliferation. Melanoma Res. 2009;19(2):63-68.
43. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59-67.
44. Colegio OR, Proby CM, Bordeaux JS, McGregor JM; Melanoma Working Group of the International Transplant Skin Cancer Collaborative (ITSCC) & Skin Care in Organ Transplant Patients, Europe (SCOPE). Prognosis of pretransplant melanoma. Am J Transplant. 2009;9(4):862.
45. Penn I. Malignant melanoma in organ allograft recipients. Transplantation. 1996;61(2):274-278.
46. Dapprich DC, Weenig RH, Rohlinger AL, et al. Outcomes of melanoma in recipients of solid organ transplant. J Am Acad Dermatol. 2008;59(3):405-417.
47. Strauss DC, Thomas JM. Transmission of donor melanoma by organ transplantation. Lancet Oncol. 2010;11(8):790-796.
48. Zwald FO, Christenson LJ, Billingsley EM, et al Melanoma Working Group of The International Transplant Skin Cancer Collaborative and Skin Care in Organ Transplant Patients, Europe. Melanoma in solid organ transplant recipients. Am J Transplant. 2010;10(5):1297-1304.
49. Penn I. Transmission of cancer from organ donors. Ann Transplant. 1997;2(4):7-12.
50. Birkeland SA, Storm HH. Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation. 2002;74(10):1409-1413.
51. Buell JF, Trofe J, Hanaway MJ, et al. Transmission of donor cancer into cardiothoracic transplant recipients. Surgery. 2001; 130(4):660-666.
52. Stephens JK, Everson GT, Elliott CL, et al. Fatal transfer of malignant melanoma from multiorgan donor to four allograft recipients. Transplantation. 2000;70(1):232-236.
53. Greene MH, Young TI, Clark WH Jr. Malignant melanoma in renal-transplant recipients. Lancet. 1981;1(8231):1196-1199.
54. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622-3634.
55. Piaserico S, Alaibac M, Fortina AB, Peserico A. Clinical and dermatoscopic fading of post-transplant eruptive melanocytic nevi after suspension of immunosuppressive therapy. J Am Acad Dermatol. 2006;54(2):338-340.
56. Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol. 2000;7(4):223-234.
57. Lens MB, Newton-Bishop JA. An association between cutaneous melanoma and non-Hodgkin's lymphoma: pooled analysis of published data with a review. Ann Oncol. 2005;16(3):460-465.
58. Hu S, Federman DG, Ma F, Kirsner RS. Skin cancer and non-Hodgkin's lymphoma: examining the link. Dermatol Surg. 2005;31(1):76-82.
59. Brewer JD, Christenson LJ, Weenig RH, Weaver AL. Effects of chronic lymphocytic leukemia on the development and progression of malignant melanoma. Dermatol Surg. 2010;36(3):368-376.
60. Tsimberidou AM, Wen S, McLaughlin P, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol. 2009;27(6):904-910.
61. Goggins W, Gao W, Tsao H. Association between female breast cancer and cutaneous melanoma. Int J Cancer. 2004; 111(5):792-794.
62. Galper S, Gelman R, Recht A, et al. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2002; 52(2):406-414.
63. van den Oord JJ, Vandeghinste N, De Ley M, De Wolf-Peeters C. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol. 1994;145(2):294-300.
64. Saenz-Santamaria MC, Reed JA, McNutt NS, Shea CR. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi. J Cutan Pathol. 1994;21(5):393-397.
65. Ramsay JA, From L, Kahn HJ. Bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol. 1995;8(2):150-154.
66. Ngan BY, Chen-Levy Z, Weiss LM, Warnke RA, Cleary ML. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med. 1988;318(25):1638-1644.
67. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335(6189):440-442.
68. Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci. 2006;43(1):1-67.
69. Hamai A, Richon C, Meslin F, et al. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation. Oncogene. 2006;25(58):7618-7634.
70. [published correction appears in Oncogene. 2007;26(8):1256]
71. Mikhail M, Velazquez E, Shapiro R, et al. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res. 2005;11(14):5153-5157.
72. Gahn B, Schafer C, Neef J, et al. Detection of trisomy 12 and Rb-deletion in CD34- cells of patients with B-cell chronic lymphocytic leukemia. Blood. 1997;89(12):4275-4281.
73. Brennan P, Scelo G, Hemminki K, et al. Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer. 2005;93(1):159-166.
74. McKenna DB, Stockton D, Brewster DH, Doherty VR. Evidence for an association between cutaneous malignant melanoma and lymphoid malignancy: a population-based retrospective cohort study in Scotland. Br J Cancer. 2003; 88(1):74-78.
75. Goggins WB, Finkelstein DM, Tsao H. Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. Cancer. 2001;91(4):874-880.
76. Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer. 2001;85(7):997-1005.
77. Adami J, Frisch M, Yuen J, Glimelius B, Melbye M. Evidence of an association between non-Hodgkin's lymphoma and skin cancer. Br Med J. 1995;310(6993):1491-1495.
78. Travis LB, Curtis RE, Boice JD Jr, Hankey BF, Fraumeni JF Jr. Second cancers following non-Hodgkin's lymphoma. Cancer. 1991;67(7):2002-2009.
79. Hisada M, Biggar RJ, Greene MH, Fraumeni JF Jr, Travis LB. Solid tumors after chronic lymphocytic leukemia. Blood. 2001; 98(6):1979-1981.
80. Travis LB, Curtis RE, Hankey BF, Fraumeni JF Jr. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst. 1992;84(18):1422-1427.
81. Spanogle JP, Clarke CA, Aroner S, Swetter SM. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study. J Am Acad Dermatol. 2010;62(5):757-767.
82. Crocetti E, Carli P. Risk of second primary cancers, other than melanoma, in an Italian population-based cohort of cutaneous malignant melanoma patients. Eur J Cancer Prev. 2004;13(1):33-37.
83. Riou JP, Ariyan S, Brandow KR, Fielding LP. The association between melanoma, lymphoma, and other primary neoplasms. Arch Surg. 1995;130(10):1056- 1061.
84. McIntosh BC, Ariyan S, Esche G, Zelterman D, Narayan D. Metachronous primary melanoma and lymphoma. Ann Plast Surg. 2010;64(2):229-232.
85. Baron J, Krol A. Management of nevi in transplant patients. Dermatol Ther. 2005;18(1):34-43.
86. Hawkins MM, Wilson LM, Burton HS, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst. 1996;88(5):270-278.
87. McKenna DB, Doherty VR, McLaren KM, Hunter JA. Malignant melanoma and lymphoproliferative malignancy: is there a shared aetiology? Br J Dermatol. 2000;143(1):171-173.
88. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47(1):1-17.
89. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80(7):883-889.
90. Foss Abrahamsen A, Andersen A, Nome O, et al. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol. 2002;13(11):1786-1791.
91. Patel P, Hanson DL, Sullivan PS, et al Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148(10):728-736.
92. Wilkins K, Turner R, Dolev JC, LeBoit PE, Berger TG, Maurer TA. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol. 2006;54(2):189-206.
93. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer. 2005;104(7):1505-1511.
94. Engels EA. Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS. 2009;23(8):875-885.
95. Hoffmann C, Horst HA, Weichenthal M, Hauschild A. Malignant melanoma and HIV infection: aggressive course despite immune reconstitution. Onkologie. 2005;28(1):35-37.
96. Rodrigues LK, Klencke BJ, Vin-Christian K, et al. Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol. 2002;138(6):765-770.
97. Pantanowitz L, Schlecht, HP, Dezube BJ. The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol. 2006;18(5):469-478.
98. Crum-Cianflone N, Hullsiek KH, Satter E, et al. Cutaneous malignancies among HIV-infected persons. Arch Intern Med. 2009;169(12):1130-1138.
99. Otley CC. Non-Hodgkin lymphoma and skin cancer: a dangerous combination. Australasian J Dermatol. 2006;47(4):231-236.
100. Kanitakis J, Baldassini S, Lora V, Euvrard S. BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients. Eur J Dermatol. 2010;20(2):167-171.